Angiotensin II type 2 receptor agonist treatment of doxorubicin induced heart failure

Basit Öğe Kaydı
dc.authoridParlakpınar, Hakan/0000-0001-9497-3468
dc.authoridYildiz, Azibe/0000-0001-5686-7867
dc.authoridOzhan, Onural/0000-0001-9018-7849
dc.authoridÇOLAK, CEMİL/0000-0001-5406-098X
dc.authoridERMIS, NECIP/0000-0001-6781-7478
dc.authorwosidUlutaş, Zeynep/JMB-6092-2023
dc.authorwosidParlakpınar, Hakan/T-6517-2018
dc.authorwosidYildiz, Azibe/ABI-7998-2020
dc.authorwosidOzhan, Onural/AAE-2356-2020
dc.authorwosidÇOLAK, CEMİL/ABI-3261-2020
dc.contributor.authorErmis, Necip
dc.contributor.authorUlutas, Zeynep
dc.contributor.authorOzhan, Onural
dc.contributor.authorYildiz, Azibe
dc.contributor.authorVardi, Nigar
dc.contributor.authorColak, Cemil
dc.contributor.authorParlakpinar, Hakan
dc.date.accessioned2024-08-04T20:53:33Z
dc.date.available2024-08-04T20:53:33Z
dc.date.issued2023
dc.departmentİnönü Üniversitesien_US
dc.description.abstractDoxorubicin (DOX) is an anthracycline derivative used for treatment of malignancies; however, its clinical use is limited by its cardiotoxicity. We investigated the effects of angiotensin II type 2 receptor agonist compound 21 (C21) on DOX induced heart failure in rat heart. We compared C21 with losartan (LOS), an AT 1 receptor antagonist used for treating heart failure. We allocated 40 rats into five groups of eight: saline treated control group, DOX group administered a single 20 mg/kg dose of DOX, DOX + C21 group administered 0.3 mg/kg C21 for 21 days following the 20 mg/kg dose of DOX, DOX + losartan (LOS) group administered a 21 day regimen of 20 mg/kg LOS following the single dose of DOX, and a DOX + LOS + C21 group administered 0.3 mg/kg C21 and 20 mg/kg LOS for 21 days following the single dose of DOX. We assessed histopathology and conducted echocardiograpic and hemodynamic measurements. Left ventricular ejection fraction (EF) was reduced only in the DOX treated group. C21, LOS and C21 + LOS therapy prevented decreased EF due to DOX. Less histopathology was observed in the DOX + LOS + C21 group than for the other treatment groups. Application of C21 decreased DOX induced cardiac injury similar to LOS. Combined use of C21 and LOS was most beneficial for DOX induced heart failure.en_US
dc.identifier.doi10.1080/10520295.2023.2187461
dc.identifier.endpage335en_US
dc.identifier.issn1052-0295
dc.identifier.issn1473-7760
dc.identifier.issue5en_US
dc.identifier.pmid36938690en_US
dc.identifier.scopus2-s2.0-85150932946en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage326en_US
dc.identifier.urihttps://doi.org/10.1080/10520295.2023.2187461
dc.identifier.urihttps://hdl.handle.net/11616/101249
dc.identifier.volume98en_US
dc.identifier.wosWOS:000950984000001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofBiotechnic & Histochemistryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAngiotensin IIen_US
dc.subjectcompound 21en_US
dc.subjectdoxorubicinen_US
dc.subjectheart failureen_US
dc.subjectlosartanen_US
dc.subjectratsen_US
dc.titleAngiotensin II type 2 receptor agonist treatment of doxorubicin induced heart failureen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu